Skip to content

To evaluate safety and efficacy of very long length drug eluting stent in the treatment of patients with coronary artery blockage.

Safety and Efficacy of Very Long Length Drug Eluting Stent in patients with Coronary Artery Stenosis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/12/011011
Enrollment
300
Registered
2017-12-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- In the treatment of patients with Coronary Artery Stenosis

Interventions

Intervention1: Drug Eluting Stent System: Patients with Coronary artery disease where stent of length greater than or equal to 35 milimeter will be deployed. Control Intervention1: Not Applicable: Not

Sponsors

G B Pant Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of Coronary artery disease (Chronic stable angina, Acute coronary syndrome) eligible for implantation of long drug eluting stent as per definition.

Exclusion criteria

Exclusion criteria: 1. Subjects with short life expectancy less than duration of 2 years (including patients with cancer, HIV/AIDS), documented LVEF less tha 30 percent, history of Cardiac Failure, Structural heart disease, Myocardiopathies, Arrhythmia or other Co-morbid conditions. 2. Subjects with History of Internal bleeding, planned Surgery (Cardiac or non-cardiac) or any similar reason that would restrict administration of dual anti platelet therapy. 3. Pregnant/lactating women during Index procedure. However, if pregnancy occurs during follow- up, the subject will not be excluded. 4. Subjects with more than Grade III Renal Insufficiency as indicated by e GFR less than 30mililitre per minute. 5. Unprotected Left Main Artery Lesion. 6. Patients with coronary artery disease where overlapping stents will be used.

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiac Events (MACE)Timepoint: 0 month,1 month, 6 months

Secondary

MeasureTime frame
Target vessel failure (TVF), Stent Thrombosis (Definite, possible, and Probable) Rate as Defined by Academic Research Consortium (ARC)Timepoint: 1 month, 6 months

Countries

India

Contacts

Public ContactDr Vivek Jindal

G B Pant Hospital

mpgirish_1999@yahoo.com9718599107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026